Lymphoma

Gilead Sciences has announced the voluntary withdrawal of idelisib from the United States market in several indications including follicular lymphoma and small lymphocytic leukemia.

A bi-specific anti-CD19/CD20 CAR T-cell therapy, C-CAR039, received a regenerative medicine advanced therapy designation and fast track designation from the FDA for treating patients with relapsed/refractory diffuse large B cell lymphoma.

Patients with mantle cell lymphoma treated in academic facilities appeared to have a longer overall survival compared those treated at with non-academic centers.

A design for the phase 3 ZILO-301 clinical trial, assessing the efficacy of zilovertamab plus ibrutinib for patients with mantle cell lymphoma, has been selected

Early relapsed appears to be an important predictor of survival among patients with mantle cell lymphoma.

Steven Devine, MD, spoke about which abstracts he found most interesting at ASH 2021.

Sattva S. Neelapu, MD, spoke about continuing to look at results from the ZUMA-5 trial to determine if axicabtagene ciloleucel can cure patients with relapsed or refractory indolent non-Hodgkin lymphoma

In an interview with ONCOLOGY®, Keith Hecht, PharmD, offers a comprehensive review of real-world treatment considerations of loncastuximab tesirine as therapy for patients with diffuse large B-cell lymphoma.

Second-line treatment of lisocabtagene maraleucel demonstrated improved quality of life in patients with large B-cell lymphoma.

Patients with previously untreated diffuse large B-cell lymphoma experienced promising responses after being treated with tafasitamab-cxix and lenalidomide plus rituximab, cyclophosphamide, doxorubicin, vincristin, and prednisone.

YTB323 led to a promising safety profile and encouraging efficacy outcomes for adult patients with relapsed/refractory diffuse large B-cell lymphoma.

Patients with high-risk large B-cell lymphoma saw durable responses when treated with axicabtagene ciloleucel.

A 27% reduction in the risk of progression or death was noted when polatuzumab vedotin was added on R-CHP vs R-CHOP for patients with intermediate- or high-risk diffuse large B-cell lymphoma who received treatment in the first line.

Sattva S. Neelapu, MD, spoke about which abstracts he was most excited to see presented at the upcoming American Society of Hematology Annual Meeting.

A positive overall response rate was achieved when patients with relapsed/refractory peripheral T-cell lymphoma were treated with duvelisib plus romidespin.

Patients with large B-cell lymphoma who were previously excluded from investigations experienced increased efficacy with the use of axicabtagene ciloleucel.

Patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma did not benefit in terms of event-free survival when treated with the CAR T-cell therapy tisagenlecleucel vs standard-of-care chemotherapy and transplant.

Glofitamab monotherapy or in combination with obinutuzumab led to strong response rates for patients with multiple relapsed or refractory follicular lymphoma.

Treatment with lisocabtagene maraleucel resulted in long-lasting responses in patients with relapsed/refractory large B-cell lymphomas.

Treatment with naratuximab emtansine and rituximab appeared to be well-tolerated with efficacious responses in a population of patients with B-cell non-Hodgkin lymphomas who were ineligible for stem cell transplant or CAR-T cell therapy.

The ZUMA-7 trial demonstrated an event-free survival improvement in patients with relapsed or refractory large B-cell lymphoma treated with axicabtagene ciloleucel.

Patients with relapsed or refractory follicular lymphoma or marginal zone lymphoma had high rates of response and overall survival with axicabtagene ciloleucel at an updated analysis of the ZUMA-5 trial.

Preclinical data show promise for the novel non-covalent Bruton tyrosine kinase inhibitor pirtobrutinib in mantle cell lymphoma with resistance to both ibrutinib and venetoclax.

A quality-of-life analysis from the phase 3 ZUMA-7 trial of axicabtagene ciloleucel in patients with relapsed or refractory large B-cell lymphoma shows favorability of the CAR T-cell therapy over standard options.

Treatment with the CAR T-cell therapy tisagenlecleucel for relapsed or refractory diffuse large B-cell lymphoma or high-grade B-cell lymphoma was favorable in both the pivotal clinical trial and the real-world setting, according to new data made available during 2021 ASH.